^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:letrozole (Aromatase inhibitor) +
    AiRuiKang (dalpiciclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    SABCS 2023
    Title:

    Dalpiciclib combination with letrozole as neoadjuvant therapy for HR-positive HER2- negative breast cancer: a single-arm, prospective exploratory clinical study

    Published date:
    12/02/2023
    Excerpt:
    The combination of dalpiciclib and letrozole has shown efficacy in downstaging and shrinking tumors in patients with early or locally advanced HR-positive/HER2-negative breast cancer.
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    SABCS 2023
    Title:

    CDK4/6 inhibitor dalpiciclib combined with letrozole as neoadjuvant therapy in postmenopausal patients with hormone receptor-positive, HER2-negative stage II-III breast cancer: a single-arm exploratory trial

    Published date:
    12/02/2023
    Excerpt:
    The ORR was 35.5% (11/31) at 8 weeks and 51.7% (15/29) at 16 weeks in patients with evaluable response….This is the first prospective study of neoadjuvant dalpiciclib in patients with HR positive, HER2-negative breast cancer. The findings suggest the promising tumor response to neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR-positive, HER2-negative breast cancer, with a manageable safety profile.
    Trial ID:
    NCT05512780